- Home
- News
- canada alberta
- rotator cuff
Rotator Cuff Articles & Analysis
17 news found
Roughly 8% of U.S. adults suffer from persistent or chronic back pain. That’s around 65 million people who are prevented from engaging in daily activities. Many are forced to miss days of work due to injury. With rising healthcare costs, many back pain sufferers think that they are left without a real solution, until they try epidural injections. An epidural injection is the infusion of ...
Milan, Italy (June 1st, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 IFSSH, IFSHT & FESSH Combined Congress organized by the International Federation of Societies for Surgery of the Hand and International Federation of Societies for Hand ...
ByKLISBio
Milan, Italy (May 11, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 Bio€quity Europe. 2022 Bio€quity Europe will be held May 16 -18, 2022 in Milan – Italy. Antonio Alessandrino, CTO and Founder of KLISBio, will be presenting on ...
ByKLISBio
Milan, Italy (March 23, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The event will be held March 22-26 in Chicago -IL. KLISBio’s designated attendee to 2022 AAOS Congress is Jason ...
ByKLISBio
Milan, Italy (March 22, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 CG Musculoskeletal Conference. Ahead of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 22-26, 2022 in Chicago, Canaccord Genuity will host its CG ...
ByKLISBio
Milan, Italy (March 21, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 Digital RESI. The conference will be held March 22-24, 2022 through a virtual platform. KLISBio’s designated attendee to Digital RESI Conference is Gabriele Grecchi, CEO ...
ByKLISBio
Milan, Italy (March 14, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to LSI 2022 Emerging MedTech Summit. LSI Annual Meeting will be held March 15 -18, 2022 in Dana Point – CA. KLISBio’s designated attendee to LSI Emerging MedTech Summit ...
ByKLISBio
InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications. This newly released paper, titled “Perspective: Why and how to use the body’s own stem cells for regeneration in musculoskeletal disorders: a primer“, was ...
Among the best of new innovations in life sciences and biomedicine being unveiled to investors and healthcare leaders at JP Morgan’s BIO Partnering conference this month is KLISBio’s silk-based biomedical technology. Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated ...
ByKLISBio
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. That’s a driving force behind KLISBio’s SILKBridge®, a first-to-market solution for peripheral nerve repair. KLISBio will introduce SILKBridge® to attendees at the American Association for Hand Surgeons Annual Meeting ...
ByKLISBio
Investors keen to get involved with a company on the forefront of human tissue regeneration will be interested to visit with KLISBio, an international medtech company bringing its silk-based biomedical technology and the first of their products, SILKBridge®, to the Biotech Showcase Jan. 10-19. KLISBio is leading a revolution in restorative surgical procedures using engineered silk ...
ByKLISBio
InGeneron, Inc., a clinical stage biotechnology company, today announced that the American Medical Association’s (AMA) Current Procedural Terminology (CPT®) Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tears. The newly published codes (0717T, 0718T) ...
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How ...
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, autologous, adipose derived regenerative cells (UA-ADRCs). This newly-released research paper, titled “First ...
InGeneron, Inc., a regenerative medicine and cell therapy company, announced today the enrollment of the first patients in a pivotal study evaluating InGeneron’s cell therapy as a way to treat partial thickness rotator cuff tears involving a partial tear in the supraspinatus tendon. The primary goal of the double-blinded, multi-center trial is to demonstrate the effectiveness of the ...
IlluminOss Medical, a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received U.S. Food and Drug Administration (FDA) de novo clearance for the IlluminOss Bone Stabilization System for treatment of impending and actual pathological fractures of the humerus, radius and ulna from metastatic bone disease. ...
IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced it has completed enrollment in its first U.S. clinical trial towards FDA approval of its IlluminOss System, the world’s first and only system of its kind which supports the treatment of fractures using patient-specific intramedullary ...